BCI
CRNX icon

Brinker Capital Investments’s Crinetics Pharmaceuticals CRNX Stock Holding History

Brinker Capital Investments’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.36M Buy
37,499
+7,004
+23% +$313K 0.01% 948
2025
Q4 		$1.42M Buy
30,495
+13,633
+81% +$607K 0.01% 1038
2025
Q3 		$702K Sell
16,862
-4
-0% -$128 0.01% 1392
2025
Q2 		$485K Sell
16,866
-814
-5% -$25.1K ﹤0.01% 1519
2025
Q1 		$593K Buy
17,680
+959
+6% +$35.8K 0.01% 1336
2024
Q4 		$855K Sell
16,721
-1,515
-8% -$84.8K 0.01% 1130
2024
Q3 		$932K Sell
18,236
-790
-4% -$40.7K 0.01% 1077
2024
Q2 		$852K Buy
19,026
+3,467
+22% +$160K 0.01% 1055
2024
Q1 		$728K Buy
+15,559
New +$609K 0.01% 1123

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return